WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Jeffrey Thomas Elliott net worth and biography

Jeffrey Elliott Biography and Net Worth

CFO of Exact Sciences

Jeff Elliott has served as our Executive Vice President and Chief Operating Officer since April 2021, and our Chief Financial Officer since November 2016. He previously served as Vice President, Business Development and Strategy, from June 2016 to November 2016. Prior to joining Exact Sciences, Mr. Elliott was with Robert W. Baird & Co., where from June 2012 to June 2016 he was a Senior Research Analyst who covered diagnostics and life science tools companies. Earlier in his career, Mr. Elliott worked in a supply chain role for Walgreens and as a consultant at Cap Gemini Ernst & Young. Mr. Elliott holds a Bachelor of Business Administration from the University of Illinois at Urbana-Champaign and a Master of Business Administration from the University of Chicago Booth School of Business. Mr. Elliott is a CFA charterholder.

What is Jeffrey Thomas Elliott's net worth?: The estimated net worth of Jeffrey Thomas Elliott is at least $649,420.20 as of March 1st, 2024. Mr. Elliott owns 10,933 shares of Exact Sciences stock worth more than $649,420 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Elliott may own. Learn More about Jeffrey Thomas Elliott's net worth.
How do I contact Jeffrey Thomas Elliott?: The corporate mailing address for Mr. Elliott and other Exact Sciences executives is 5505 ENDEAVOR LANE, MADISON WI, 53719. Exact Sciences can also be reached via phone at (608) 284-5700 and via email at [email protected]. Learn More on Jeffrey Thomas Elliott's contact information.
Has Jeffrey Thomas Elliott been buying or selling shares of Exact Sciences?: Jeffrey Thomas Elliott has not been actively trading shares of Exact Sciences over the course of the past ninety days. Most recently, Jeffrey Thomas Elliott sold 2,412 shares of the business's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $59.32, for a transaction totalling $143,079.84. Following the completion of the sale, the chief financial officer now directly owns 10,933 shares of the company's stock, valued at $648,545.56. Learn More on Jeffrey Thomas Elliott's trading history.
Who are Exact Sciences' active insiders?: Exact Sciences' insider roster includes Brian Baranick (Insider), Sarah Condella (SVP), Kevin Conroy (CEO), D. Coward (Insider), Everett Cunningham (Insider), James Doyle (Director), Jeffrey Elliott (CFO), James Herriott (General Counsel), Torsten Hoof (Insider), Daniel Levangie (Director), Graham Lidgard (Insider), Jacob Orville (Insider), and Katherine Zanotti (Director). Learn More on Exact Sciences' active insiders.
Are insiders buying or selling shares of Exact Sciences?: In the last twelve months, Exact Sciences insiders bought shares 1 times. They purchased a total of 19,500 shares worth more than $1,001,325.00. In the last twelve months, insiders at the medical research company sold shares 35 times. They sold a total of 75,348 shares worth more than $4,597,043.93. The most recent insider tranaction occured on November, 13th when CEO Kevin T Conroy bought 19,500 shares worth more than $1,001,325.00. Insiders at Exact Sciences own 1.4% of the company. Learn More about insider trades at Exact Sciences.
Information on this page was last updated on 11/13/2024.

Jeffrey Thomas Elliott Insider Trading History at Exact Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/1/2024	Sell	2,412	$59.32	$143,079.84	10,933
2/27/2024	Sell	2,710	$56.89	$154,171.90	8,054
2/21/2024	Sell	1,493	$61.50	$91,819.50	3,703
2/15/2024	Sell	1,888	$61.43	$115,979.84	2,084
8/21/2023	Sell	30,210	$82.92	$2,505,013.20
2/28/2023	Sell	4,233	$61.12	$258,720.96	29,241
2/15/2023	Sell	1,866	$65.59	$122,390.94	22,655
2/13/2023	Sell	1,158	$64.55	$74,748.90	20,549
3/1/2022	Sell	4,050	$76.69	$310,594.50
2/23/2022	Sell	1,557	$69.05	$107,510.85
2/15/2022	Sell	1,839	$79.55	$146,292.45
7/29/2021	Sell	38,361	$111.40	$4,273,415.40
3/2/2021	Sell	4,230	$139.24	$588,985.20	45,223
2/24/2021	Sell	4,449	$136.30	$606,398.70	49,613
7/29/2020	Sell	8,746	$95.58	$835,942.68	59,109
2/27/2020	Sell	1,627	$80.27	$130,599.29	57,743
2/25/2020	Sell	4,910	$85.11	$417,890.10	59,217
7/30/2019	Sell	9,845	$105.60	$1,039,632.00	41,012
2/28/2019	Sell	2,447	$93.20	$228,060.40
1/24/2019	Sell	90,909	$78.90	$7,172,720.10	124,120
7/30/2018	Sell	8,984	$57.78	$519,095.52	22,690
2/26/2018	Sell	2,982	$42.34	$126,257.88
7/31/2017	Sell	5,846	$39.41	$230,390.86	19,861

Jeffrey Thomas Elliott Buying and Selling Activity at Exact Sciences

Exact Sciences Company Overview

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Today's Range

Now: $59.40

$55.98

$59.70

50 Day Range

MA: $61.91

$49.33

$71.93

2 Week Range

Now: $59.40

$40.62

$79.62

Volume

3,273,828 shs

Average Volume

2,615,913 shs

Market Capitalization

$10.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24